07:56 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending a change to the marketing authorization of Novartis' (NOVN.SW) Cosentyx. The new indication covers adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa who have had an inadequate response to conventional systemic therapy, according to a Friday notice. The recommendation remains subject to a final decision by the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.